IRCT20200105046010N102招募中Unknown
Bioequivalence study of Dulotegravir 50 mg tablet (Tivimex)manufactured by Sobhan trading group versus originator brand in healthy volunteers in the fed condition
Sobhan trading group0 个研究点目标入组 24 人开始时间: 待定最近更新:
试验速览
- 阶段
- Unknown
- 状态
- 招募中
- 发起方
- 入组人数
- 24
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 years 至 55 years（—）
- 性别
- All
入选标准
- •General Health (Liver, Heart, and Kidney)
- •Body Mass Index (18-28)
- •Informed consent
- •Age (18-55 years old)
排除标准
- •History of cardiovascular disease
- •History of liver and kidney disease
- •Alcohol and drug addiction
- •History of allergy to Dulotegravir
研究者
相似试验
尚未招募
Unknown
In vivo Bioequivalence study of Dolutegravir tabletsIRCT20220211053992N36Tabriz University of Medical Sciences24
暂停
1 期
Bioequivalence Study of 50 mg Dolutegravir Film-coated Tablets in Healthy Thai VolunteersBioequivalence Study of 50 mg Dolutegravir Film-caoted Tablets in Healthy Thai VolunteersTCTR20220907001nison Laboratories Co., Ltd.30
尚未招募
Unknown
Benefits and safety of major medicines in HIV patients.CTRI/2024/04/065522Institute of Medical Sciences, Banaras Hindu University
已完成
3 期
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir Plus Lamivudine With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Subjects (Gemini 1)Infection, Human Immunodeficiency VirusHIV InfectionsNCT02831673ViiV Healthcare719
已完成
3 期
An Efficacy, Safety, and Tolerability Study Comparing Dolutegravir (DTG) Plus Lamivudine (3TC) With Dolutegravir Plus Tenofovir/Emtricitabine in Treatment naïve HIV Infected Participants (Gemini 2)Infection, Human Immunodeficiency VirusHIV InfectionsNCT02831764ViiV Healthcare722